ArticleBMC oral health2025
Edaravone attenuates doxorubicin-induced oral mucosal injury via modulation of oxidative stress, inflammatory signaling, and the SIRT1/TLR4/NF-kB/ACE2 axis in rats.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral mucositis (OM) is a common complication of chemotherapy, particularly with anthracyclines like doxorubicin (DOX), which induce oxidative stress and inflammation. This study investigated the protective effects of edaravone (EDO), a free radical scavenger, against DOX-induced oral mucosal injury.
methodsTwenty-eight male Wistar rats were randomly divided into four groups (n = 7): Control, DOX (18 mg/kg, i.p., days 19-21), and two EDO + DOX groups (1 or 30 mg/kg EDO daily for 21 days). On day 22, tongue tissues and plasma were analyzed for oxidative stress markers (MDA, GSH, SOD, TAS, TOS) and cytokines (TNF-α, IL-6, IL-1β, IL-10). NF-κB, SIRT1, and TLR4 expression were assessed via immunohistochemistry and ELISA, while ACE2 expression was evaluated by immunohistochemistry.
resultsDOX significantly upregulated ACE2 (p < 0.001), TLR4 (p < 0.001), NF-κB (p < 0.001), and proinflammatory cytokines in plasma and tongue tissue (TNF-α, IL-6, IL-1β; all p < 0.01), while reducing IL-10 (p < 0.001), GSH (p = 0.002), SOD (p = 0.001), and SIRT1 (p < 0.001). EDA treatment reduced ACE2 and TLR4 expression, with 30 mg/kg normalizing ACE2 (p = 0.978 vs. control). EDO restored antioxidant markers and significantly lowered MDA, TOS, cytokines, and NF-κB (all p < 0.05). Histological injury and inflammation scores also improved significantly (p < 0.001).
conclusionEdaravone effectively attenuates DOX-induced mucosal injury by modulating oxidative stress, inflammatory signaling, and TLR4/ACE2 pathways, suggesting therapeutic potential in mucosal protection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.